New kinase review has no direct creatine takeaway

Key Takeaways

• This is a narrative scientific review, not a creatine trial and not a supplement study.
• The paper highlights shared disease pathways including SRC/PI3K/AKT, JAK/STAT, MAPK, and FAK-integrin signalling.
• Because the source is mechanistic and broad, it cannot show that creatine prevents, treats, or alters these diseases.
• For people considering creatine, the strongest practical evidence still comes from direct supplementation research, especially on creatine monohydrate.
• Standard evidence-based creatine use remains roughly 3 to 5 g/day, with optional loading of about 20 g/day split into 4 doses for 5 to 7 days.
• If you want to use creatine, choose decisions based on human supplementation data, not indirect pathway speculation.

What the review actually found

The new paper in Signal Transduction and Targeted Therapy is a high-level review of non-receptor tyrosine kinases, or NRTKs: intracellular enzymes that help relay signals controlling cell survival, immune activity, growth, stress responses, and protein interactions. Its central message is that several NRTK-linked pathways appear again and again across major disease categories, especially cancer, cardiovascular disease, neurodegenerative disease, autoimmune conditions, and metabolic disease.

The review specifically highlights recurring signalling networks such as SRC/PI3K/AKT, JAK/STAT, MAPK, and FAK-integrin. According to the abstract, these pathways contribute to inflammation, immune modulation, metabolic reprogramming, and cellular stress responses. The authors’ goal was not to test a single treatment, but to present a broader map of where these signalling systems converge across diseases and where they differ.

That matters scientifically because shared “nodal points” in signalling can help drug developers identify targets that might be relevant in more than one disease area. The paper also discusses existing FDA-approved drugs and ongoing clinical trials aimed at NRTK-related targets.

What it does not do is test creatine, compare creatine with any drug, or show that creatine supplementation alters these pathways in people. For readers of a creatine site, that distinction is crucial. This paper is useful background on disease biology, but it is not new evidence that creatine affects kinase signalling in a clinically meaningful way.

Why this is not a creatine study

The most important point for readers is simple: this source does not investigate creatine supplementation. It is a review article about signalling biology and therapeutic implications of NRTKs. That means any link to creatine would be indirect unless supported by separate, direct research.

In practice, papers like this can tempt over-interpretation. Because creatine is involved in cellular energy buffering through the phosphocreatine system, readers may assume that any paper mentioning metabolism, stress responses, or signalling has immediate supplement implications. But mechanistic overlap is not the same as evidence of benefit. A pathway can be relevant to disease without a given supplement meaningfully changing that pathway in humans.

For example, this review discusses broad intracellular cascades that sit at the centre of complex disease processes. To turn that into a real-world creatine claim, you would need studies showing at least one of the following:

• that creatine changes those pathways in humans or relevant clinical populations,
• that those pathway changes are reproducible and dose-related, and
• that they translate into better symptoms, function, risk markers, or outcomes.

This paper provides none of that. So while it may be useful to scientists thinking about future hypotheses, it should not change how everyday users approach creatine guides, product selection, or dosing. Readers looking for practical supplementation advice are still better served by direct human evidence on creatine monohydrate, not by broad signalling reviews.

How the source was designed and its limits

This article is a review, not a randomized controlled trial, cohort study, or meta-analysis of creatine use. Based on the abstract provided, it aims to offer a holistic view of NRTKs in cellular homeostasis and disease, emphasizing convergent and divergent signalling roles across multiple systems. Reviews can be valuable because they synthesize a large field, identify common patterns, and point to promising therapeutic targets.

But reviews also have clear limits. They generally do not produce new clinical outcome data, and their conclusions depend on the quality and balance of the literature they include. A broad review spanning cancer, cardiovascular, neurodegenerative, autoimmune, and metabolic disease is especially useful for generating perspective, yet necessarily less precise for making supplement-level recommendations.

There are several limitations creatine readers should keep in mind:

• No direct intervention: no creatine dosing, timing, or formulation was tested.
• No supplement outcomes: no strength, body composition, cognition, symptoms, or biomarkers tied to creatine use were reported.
• No causal proof for creatine: pathway mapping cannot establish that creatine will beneficially modify those pathways.
• Therapeutic context differs: kinase-targeting drugs act very differently from a dietary supplement such as creatine monohydrate.

In short, this is a useful disease-signalling overview, but it sits several steps removed from decisions such as whether to use creatine, how much to take, or which formula to buy from the creatine product catalog.

What it means for people taking creatine in practice

For most readers, the practical implication is conservative: this review does not change evidence-based creatine use. If you take creatine for strength, power, training capacity, or lean mass support, the best-supported approach remains creatine monohydrate at standard doses established in direct supplementation research.

Mainstream sports nutrition guidance still centres on two common options:

• Maintenance only: about 3 to 5 g per day.
• Optional loading: about 20 g per day split into 4 doses for 5 to 7 days, followed by maintenance.

Those numbers come from the broader creatine literature, not from this kinase review. If you want help estimating intake, use a creatine dosage calculator. If you are comparing products, remember that the form with the strongest evidence base is still monohydrate, which is why it dominates serious best creatine rankings and many independent creatine brand reviews.

Who should be especially careful not to over-read this paper? Anyone hoping for evidence that creatine can prevent or treat complex diseases named in the review. There is ongoing interest in creatine beyond sport, but that evidence is condition-specific and often much less definitive than the performance literature. A disease-signalling review does not close that gap.

If you have a medical condition or take prescription drugs, especially in oncology or immunology settings, decisions should be based on clinician guidance and direct clinical evidence, not on indirect pathway similarities.

How this fits the existing creatine evidence

The broader creatine evidence base is strong for certain uses and much weaker for others. The best-supported claims are still in sports nutrition: creatine monohydrate can help increase high-intensity exercise capacity and support gains in strength and lean mass when paired with training. That is why position statements such as the ISSN review by Kreider et al. remain more informative for users than a general disease-signalling paper.

Likewise, common questions about safety, water retention, kidney myths, and practical dosing are addressed more directly in Antonio et al. (2021) and other direct creatine summaries. Those sources deal with actual supplementation evidence rather than inferring effects from adjacent molecular biology.

Where does the new review still matter? It provides context for why metabolism and signalling remain active areas of biomedical research. Cellular pathways such as PI3K/AKT, JAK/STAT, and MAPK are deeply relevant to disease. But relevance of a pathway does not automatically validate a supplement intervention.

A good rule for readers is this: prefer direct human creatine evidence over mechanistic enthusiasm. Mechanisms can help explain or inspire research, but they do not replace outcome studies. That is especially important in areas like neurodegeneration, cardiometabolic health, or autoimmunity, where the biological story may be interesting yet the supplementation evidence may still be preliminary, mixed, or population-specific.

Bottom line for readers

This review is important for scientists because it organizes how non-receptor tyrosine kinase pathways overlap across major diseases and where drug development may target them. For creatine users, however, the correct takeaway is restrained: it is not new evidence for or against creatine.

If your goal is better gym performance or a straightforward, evidence-based supplement routine, nothing in this paper meaningfully changes the current picture. Creatine monohydrate remains the best-studied form, standard daily dosing remains the practical norm, and real-world decisions should still be based on human supplementation trials and consensus reviews.

If your interest is disease prevention or treatment, this paper is best read as a map of cellular signalling rather than a guide to supplementation. It may eventually help shape future hypotheses about metabolism, stress responses, and therapeutic combinations, but those possibilities need to be tested directly before they become actionable advice.

The safest conclusion is also the most accurate: this is a useful review of disease biology, not a creatine breakthrough. Until direct evidence says otherwise, people considering creatine should stick to established guidance, choose reputable monohydrate products, and separate exciting mechanisms from demonstrated outcomes.

Creatine context: what this paper changes and what it doesn't

• 0 creatine doses tested in this review — The source is a disease-signalling review, not a creatine intervention study.
• 4 core signalling pathways highlighted — SRC/PI3K/AKT, JAK/STAT, MAPK, and FAK-integrin.
• 3-5 g/day typical creatine maintenance dose — Mainstream evidence-based guidance for creatine monohydrate.
• 20 g/day common loading protocol — Usually split into 4 doses for 5-7 days.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN